聚乙二醇干扰素联合利巴韦林治疗不同年龄慢性丙型肝炎患者疗效比较

doi:10.3969/j.issn.1672-5069.2015.02.020

Abstract

Wang Yongsu, Zhang Lin, Ma Qiang, et al.. PEG-IFNα-2a plus ribavirin in treatment of patients with chronic hepatitis C:does the age influence the efficacy[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(3): 294-295.

References

[1] Omata M,Kanda T,Yu ML,et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int,2012,6:409-435.
[2] European Association for the Study of the Liver.EASL clinical practice guidelines:management of hepatitis C virus infection .J Hepatol,2011,55:245-264.
[3] Seeff LB. The history of the “natural history” of hepatitis C （1968-2009）. Liver Int,2009,29（suppl 1）:89-99.
[4] 李敏然,孙杏丽,任桂芳,等. 聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎的临床观察.国际病毒学杂志,2013,20（1）：22-23.
[5] Honda T,Katano Y,Shimizu,et al. Efficacy of peginterferonα-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis.Liver Int,30（4）:527-537.
[6] 郑莹莹,范晓红,王力芬,等.聚乙二醇干扰素α-2a联合利巴韦林治疗老年慢性丙型肝炎的疗效及安全性.临床肝胆病杂志,2011,27（8）：821-823.
[7] 蔡少平,张文瑾,何卫平,等. 干扰素联合利巴韦林治疗高龄慢性丙型肝炎患者1例. 实用肝脏病杂志,2013,16（4）：365.
[8] Huang CF,Chuang WL,Yu ML.Chronic hepatitis C infection in the elderly. Kaohsiung J Med Sci,2011,27:533-537.
[9] 中华医学会肝病学分会、中华医学会传染病与寄生虫病学分会.丙型肝炎防治指南. 中华肝脏病杂志,2004,12:194-198.
[10] 曹静静,薛博瑜. 中医药治疗丙型肝炎的研究.长春中医药大学学报,2012,28（2）：71-73.
[11] 王晓峰,程勇前,张文瑾,等.丙型肝炎病毒感染至临床诊断肝癌的病程经过. 肝脏,2004,9（1）：8-10.
[12] Honda T,Katano Y,Shimizu J,et al.Efficacy of peginterferon α-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis. Liver Int,2010,30（4）:527-537.
[13] 王建军,赵平. 老年HCV感染者抗病毒治疗研究进展. 实用肝脏病杂志,2012,15（5）：463.
[14] McHutchison JG,Gordon SC,Schiff ER,et al.Interferon alfα-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.N Engl J Med,1998,339（21）:1458-1492.

[1]	Pan Meimin, Li Wenjuan, Jiang Fangqing, et al.. Changes of serum IL-17A,fibroblast growth factor and IL-7 levels in patients with hepatitis C virus infection [J]. Journal of Practical Hepatology, 2019, 22(6): 840-843.
[2]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[3]	Zhu Yage, Liu Jinfeng.. Therapeutic efficacy of adenosine methionine and glycyrrhizin combination in treatment of patients with alcoholic cirrhosis and its effect on serum BGP levels [J]. Journal of Practical Hepatology, 2019, 22(6): 872-875.
[4]	Deng Haohui, Li Xiaoqiang, Gao Hongbo, et al. Comparison of HCV genotypes in patients with HIV/HCV co-infection and HCV mono-infection in Guangzhou [J]. Journal of Practical Hepatology, 2019, 22(5): 656-659.
[5]	Zhao Fangfang, Zhai Yongzhen, Feng Guohe. Efficacy and safety of autologous peripheral blood stem cell transplantation in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 700-703.
[6]	Zhang Zhicheng, Yuan Guangqi, Mo Chanjun. Impact of blood supply on efficacy of hepatic artery embolization in treatment of patients with hepatic hemangioma [J]. Journal of Practical Hepatology, 2019, 22(5): 736-739.
[7]	Yan Lingling, Hu Donghui, Huang Yanfang. Influence of ademetionine combined with polyene phosphatidylcholine on clinical efficacy and laboratory index in patients with intrahepatic cholestasis of pregnancy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 530-533.
[8]	Yuan Chunhui, Li Chunyu, Li Hongli. Efficacy of pegylated interferon α -2b in the treatment of patients with serum HBeAg positive chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 353-356.
[9]	Liu Li，Li Junyi，Du Yingrong. Efficacy and safety of sofosbuvir/daclatasvir in the treatment of patients with chronic hepatitis C and hepatitis C cirrhosis:An real-world study [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 361-364.
[10]	Ma Xiaosu, Pei Renming Zhang Tingting. Comparison of magnetic resonance cholangiopancreatography with color Doppler ultrasound in diagnosis of patients with common bile duct stones [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 433-436.
[11]	Jiang Yi, Liu Bing. Comparison of clinical features and histopathological activity index between patients with chronic hepatitis B and chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 188-191.
[12]	Wu Jing, Dong Baoji, Wu Chao. Comparison of PD-1 receptor on peripheral blood follicular helper T lymphocyte surface in chronic hepatitis C patients with low and high serum viral loads [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 192-195.
[13]	Wu Yaping, Zhou Bingqing, Jiang Peili. Risk factors of severe hepatic fibrosis in patients with chronic hepatitis C with previous paid blood donation [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 196-199.
[14]	Yang Zhenjie, Li Hongtao, Wang Jian, Li Xia, Chen Yuan. Efficacy of combination of pegylated interferon-α-2a and ribavirin in treatment of patients with compensated hepatitis C cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 232-235.
[15]	Wang Xiuqing, Ma Yanjun, Zhan Jinli. Efficacy of transcatheter arterial chemoembolization and ultrasound-guided microwave ablation in the treatment of patients with hepatocellular carcinoma at special sites [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 260-263.

PEG-IFNα-2a plus ribavirin in treatment of patients with chronic hepatitis C:does the age influence the efficacy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments